ImportantThis guide provides general information and cannot replace advice based on your pathology, scans and medical history.
After endometrial cancer surgery, further treatment is based on the final pathology and risk profile. Some patients need no additional treatment, while others may benefit from vaginal brachytherapy, pelvic radiotherapy, systemic therapy or combinations depending on stage, grade, histology, lymphovascular invasion, nodes and molecular features.
Endometrial cancer, that is cancer of the lining of the uterus, is often treated first with surgery. After surgery, the final histopathology report decides whether any further treatment is needed. Some patients need only follow-up. Others may need vaginal brachytherapy, pelvic radiation, chemotherapy, or a combination.
- Post-surgery treatment in endometrial cancer is guided by individual histopathological and molecular risk.
- Vaginal brachytherapy delivers highly focused internal radiation to the vaginal vault with minimal side effects.
- Pelvic external-beam radiotherapy is added when deeper invasion, nodal risk or cervical extension is present.
- Modern molecular classification (POLE, MMRd, p53) is increasingly transforming adjuvant therapy choices.
Which pathology findings matter after endometrial cancer surgery?
The post-operative report usually includes tumour type (endometrioid, serous, clear cell), histological grade (Grade 1, 2, or 3), depth of myometrial invasion (less than or greater than 50%), cervical stromal involvement, lymphovascular space invasion (LVSI), lymph node status, surgical margins and pathological stage.
The doctor may order additional molecular classification tests to properly estimate risk. These factors help estimate recurrence risk. Treatment is not based only on the word 'cancer'; it is based on the details of the report.
What is vaginal brachytherapy and when is it used?
Vaginal brachytherapy is internal radiation delivered to the upper vagina/vaginal vault region, where recurrence risk may be higher in selected patients. It is usually a focused, outpatient treatment and is different from whole-pelvis external radiation.
Because vaginal brachytherapy concentrates dose only on the vaginal cuff surface, bladder and rectal exposures are extremely low, resulting in excellent tolerance and minimal disruption to daily life. Pelvic external-beam radiation may be considered when the risk pattern suggests a need to treat a wider pelvic lymphatic region.
When is pelvic radiation considered?
Patients often ask: 'If the uterus has already been removed, why is radiation needed?' The reason is that microscopic cancer cells can sometimes remain in pelvic lymph node drainage basins or soft tissues at risk even when all visible disease has been surgically removed.
Radiation is advised only when the estimated risk of locoregional recurrence justifies treatment. In higher-risk groups, adjuvant pelvic radiation significantly reduces pelvic relapse rates.
Why molecular classification increasingly matters
Worldwide, the management of endometrial cancer has moved towards individualized treatment based on molecular classification (such as the ProMisE or ESGO/ESTRO/ESP guidelines). The molecular classification categorises endometrial cancers into distinct groups - POLE-mutated, mismatch repair-deficient (MMRd), p53-abnormal, and no specific molecular profile (NSMP) - each with substantially different risks of recurrence.
In today's day and age, it becomes important to adequately categorise a patient's endometrial cancer diagnosis to understand her need for adjuvant therapy, instead of relying on an outdated one-size-fits-all approach.
For a post-operative review in Surat, keep the operation note, final HPR, imaging, discharge summary and any tumour-board advice available for consultation with Dr. Parth Verma.
How an individual consultation changes the answer
Online information describes patterns, not personal eligibility. A radiation oncology recommendation begins by confirming the pathology and stage, reviewing the actual scans and understanding previous treatment. The doctor then defines the intent: cure, reduction of recurrence risk, organ preservation, control of a limited metastatic site or relief of symptoms.
Your anatomy, symptoms, general fitness and priorities can change the balance between options that look similar on paper. Planning also reveals whether dose limits for nearby organs can be met. This is why a consultation may appropriately reach a different conclusion from a general article without either being contradictory.
A useful appointment should leave you able to explain what is being recommended, why it fits your case, what alternatives were considered, which uncertainties remain and what happens next. You do not need to decide during the first conversation if the situation is not urgent.
Turn general information into a useful medical discussion
Start by writing down the parts of this guide that appear relevant and the parts that do not match what you have been told. Do not use an online article to change medicines, skip an investigation or delay treatment on your own. Instead, ask the treating team to connect the general principle to your diagnosis, stage and treatment intent. If a term in the report is unclear, request the exact wording and an explanation in language you can repeat back.
Bring the pathology report, the actual CT, MRI or PET images as well as their written reports, operation notes, previous treatment summaries, current medicines and recent blood tests. Previous radiation needs special attention: a safe re-irradiation opinion may require the original digital plan, dose distribution and structure set, not only a discharge card. Sending records before the visit can leave more appointment time for decisions and questions.
It can help to create a one-page timeline with the biopsy date, major scan dates, surgery, medicine cycles and the recommendation currently being considered. Add your most important priorities, such as preserving an organ, reducing travel, maintaining work, fertility, urinary or bowel function, or understanding the chance of needing additional treatment. These priorities do not replace cancer-control considerations, but they help the doctor compare medically reasonable options in a way that fits your life.
Finally, distinguish urgent symptoms from decision questions. New weakness, severe bleeding, breathing difficulty, uncontrolled pain, confusion, fever or inability to drink may need prompt hospital assessment rather than a routine appointment or WhatsApp exchange. For a non-urgent decision, leave the consultation with a written next step, the expected time frame and a contact point for questions that arise after you review the discussion with your family.
Look beyond reassuring words and technology labels
Cancer information often uses words such as precision, advanced, targeted or minimally invasive. These terms can describe useful capabilities, but they do not prove that a treatment is appropriate or superior for one person. Ask what clinical problem a technique solves, what evidence supports it for your diagnosis and stage, and whether a simpler or different option could achieve the same goal. A machine brand, session count or dramatic dose image should never replace an explanation of treatment intent and expected benefit.
Useful comparisons include the complete pathway: preparation, other treatments, likely side effects, recovery, follow-up and the chance that additional treatment will be needed. Ask the clinician to separate common effects from rare serious risks and to state where evidence is strong, uncertain or based mainly on patient selection. If percentages are quoted, ask which group they came from and whether that group resembles your situation.
High-quality care also includes processes patients may not see: pathology and imaging review, contouring, peer discussion, physics quality assurance, image guidance, symptom support and a plan for anatomical change. These processes are less marketable than a machine name but often determine whether technology is used well. The best consultation should make the reasoning clearer, not simply make the treatment sound impressive.
Questions worth bringing with you
- What was the depth of myometrial invasion and tumour grade on my pathology report?
- Was lymphovascular space invasion (LVSI) or cervical involvement observed?
- Am I a candidate for vaginal cuff brachytherapy alone instead of external pelvic radiation?
- Is molecular classification testing (POLE, MMR, p53) recommended for my tumor?
- Will systemic chemotherapy be required alongside radiation?
- What is the follow-up surveillance schedule over the next 5 years?
Frequently asked questions
Why might radiation be needed if the uterus has been removed?+
Because microscopic cancer cells can remain in pelvic lymph nodes or vaginal apex tissues at risk even after all visible disease is removed.
Is vaginal brachytherapy the same as pelvic radiation?+
No. Vaginal brachytherapy is a focused, outpatient internal treatment to the vaginal cuff, while pelvic radiation treats a wider region including pelvic lymph nodes.
Does every endometrial cancer patient need radiation?+
No. Patients with low-risk early-stage endometrial cancer often require only careful observation and surveillance after complete surgery.
These references support the general educational information above. They do not establish which treatment is appropriate for one person.
ESTRO (European Society for Radiotherapy & Oncology) GuidelinesASTRO Clinical Practice Guidelines in Radiation OncologyTata Memorial Centre Evidence-Based Clinical Practice Guidelines